Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Open Label, Multicenter Study of Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

NCT04858256 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT04858256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04858256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Open Label, Multicenter Study of Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
March 29, 2023
Completion date
November 30, 2028
Enrollment
100 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoproliferative disorders, t-cell neoplasm